BR112013011420A2 - vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase - Google Patents
vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníaseInfo
- Publication number
- BR112013011420A2 BR112013011420A2 BR112013011420A BR112013011420A BR112013011420A2 BR 112013011420 A2 BR112013011420 A2 BR 112013011420A2 BR 112013011420 A BR112013011420 A BR 112013011420A BR 112013011420 A BR112013011420 A BR 112013011420A BR 112013011420 A2 BR112013011420 A2 BR 112013011420A2
- Authority
- BR
- Brazil
- Prior art keywords
- leishmaniasis
- smt
- sterol
- vaccines
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41136610P | 2010-11-08 | 2010-11-08 | |
PCT/US2011/059600 WO2012064659A1 (en) | 2010-11-08 | 2011-11-07 | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013011420A2 true BR112013011420A2 (pt) | 2016-08-02 |
Family
ID=45002141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013011420A BR112013011420A2 (pt) | 2010-11-08 | 2011-11-07 | vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120114688A1 (pt) |
EP (1) | EP2637687B1 (pt) |
BR (1) | BR112013011420A2 (pt) |
EA (1) | EA201390676A1 (pt) |
ES (1) | ES2859673T3 (pt) |
WO (1) | WO2012064659A1 (pt) |
ZA (1) | ZA201303726B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833534B2 (en) | 2006-04-10 | 2010-11-16 | Infectious Disease Research Institute | Compounds and methods for diagnosis and treatment of leishmaniasis |
ES2628743T3 (es) | 2008-07-03 | 2017-08-03 | Infectious Disease Research Institute | Proteínas de fusión y su uso en el diagnóstico y tratamiento de la leishmaniasis |
WO2012061910A2 (pt) * | 2010-11-08 | 2012-05-18 | Universidade Federal Do Rio De Janeiro | Principais domínios e epítopos imunoprotetores da nucleosideo hidrolase de leishmania (l) donovani para uso em vacinação, imunoterapia e diagnóstico |
US9909114B2 (en) | 2013-03-28 | 2018-03-06 | Infectious Disease Research Institute | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
US20160158329A1 (en) * | 2013-03-28 | 2016-06-09 | Infectious Disease Research Institute | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
CN108079290A (zh) * | 2013-05-14 | 2018-05-29 | 硕腾服务有限责任公司 | 包含免疫刺激性寡核苷酸的新颖疫苗组合物 |
US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
BR112016015422A2 (pt) | 2013-12-31 | 2017-10-24 | Infectious Disease Res Inst | formulações de vacina de frasco único |
WO2020243115A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
CN117120087A (zh) | 2020-12-23 | 2023-11-24 | 高级健康研究所 | 茄尼醇疫苗助剂及其制备方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4816566A (en) | 1983-06-01 | 1989-03-28 | Hoffmann-La Roche, Inc. | Polypeptides having interferon activity |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
DK0641192T3 (da) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Anordning til transmucosal lægemiddelafgivelse |
SG49909A1 (en) | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
US5359681A (en) | 1993-01-11 | 1994-10-25 | University Of Washington | Fiber optic sensor and methods and apparatus relating thereto |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
CN1296416A (zh) | 1998-04-09 | 2001-05-23 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂组合物 |
EP1104306B1 (en) | 1998-08-10 | 2006-01-11 | Antigenics Inc. | Compositions of cpg and saponin adjuvants and methods of use thereof |
IL145982A0 (en) | 1999-04-19 | 2002-07-25 | Smithkline Beecham Biolog | Vaccines |
US7472098B2 (en) | 2000-02-14 | 2008-12-30 | Ubs Financial Services, Inc. | System and method for execution of trades made pursuant to stock option and purchase plans |
US7189522B2 (en) | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
AU2007354917B2 (en) | 2006-09-26 | 2013-06-06 | Access To Advanced Health Institute | Vaccine composition containing synthetic adjuvant |
US8916168B2 (en) * | 2007-07-13 | 2014-12-23 | Infectious Disease Research Institute | Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis |
BRPI0912768A2 (pt) * | 2008-05-21 | 2016-05-17 | Infectious Disease Res Inst | vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose |
-
2011
- 2011-11-07 US US13/290,834 patent/US20120114688A1/en not_active Abandoned
- 2011-11-07 BR BR112013011420A patent/BR112013011420A2/pt not_active Application Discontinuation
- 2011-11-07 ES ES11785541T patent/ES2859673T3/es active Active
- 2011-11-07 WO PCT/US2011/059600 patent/WO2012064659A1/en active Application Filing
- 2011-11-07 EP EP11785541.1A patent/EP2637687B1/en active Active
- 2011-11-07 EA EA201390676A patent/EA201390676A1/ru unknown
-
2013
- 2013-05-22 ZA ZA2013/03726A patent/ZA201303726B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201390676A1 (ru) | 2013-11-29 |
US20120114688A1 (en) | 2012-05-10 |
WO2012064659A1 (en) | 2012-05-18 |
ZA201303726B (en) | 2014-07-30 |
ES2859673T3 (es) | 2021-10-04 |
EP2637687A1 (en) | 2013-09-18 |
EP2637687B1 (en) | 2021-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013011420A2 (pt) | vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase | |
IL285106A (en) | Clean nucleic acids are suitable for analyzing the human microbiome and its parts | |
BRPI1009847A2 (pt) | conectores médicos e métodos de uso | |
BRPI1005960A2 (pt) | sistema de implante e ultilização de um sistema de implante | |
HK1210044A1 (en) | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment | |
EP2575651A4 (en) | INTRAMEDULLARY FASTENING ASSEMBLY AND METHOD OF USE | |
HK1211826A1 (en) | Method of uniform crimping and expansion of medical devices | |
BR112013023135A2 (pt) | elemento de suporte para o corpo humano e método para sua realização | |
BR112014007217A2 (pt) | método e dispositivo de fixação cirúrgica | |
BRPI0912768A2 (pt) | vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose | |
HK1199401A1 (en) | Pharmaceutical formulations and the use thereof for the treatment of peanut allergy | |
EP2643029A4 (en) | PREPARATIONS AND / OR FORMULATIONS BASED ON PROTEINS RETICULATED WITH POLYSACCHARIDES | |
BR112013023743A2 (pt) | anticorpo de fator de tecidos humanos e usos do mesmo | |
HK1222331A1 (zh) | 修飾的繆勒抑制物質 蛋白及其用於疾病治療的用途 | |
BR112013011932A2 (pt) | dispositivo para tratamento de ejaculação precoce ou estímulo de órgão masculino | |
GB2479598B (en) | Methods and systems for inducing hyperthermia | |
BR112013014751A2 (pt) | sistema de manta para esterilização e métodos de uso | |
PL3080793T3 (pl) | Urządzenie do symulowania działania ludzkiego żołądka i/lub ludzkiego jelita | |
ZA201507407B (en) | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis | |
HK1196379A1 (zh) | 用作抗原掩蔽劑的人乳鐵蛋白衍生肽 | |
FI20095134A (fi) | Menetelmä pitolaitteen käyttämiseksi ja pitolaite | |
EP2981287A4 (en) | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis | |
EP2536342A4 (en) | INTRAMEDULLARY DEVICE AND METHOD OF USING THE SAME | |
IL233697A0 (en) | Theranostic methods and systems for the diagnosis and treatment of malaria | |
BR112014006593A2 (pt) | dispositivo médico para inserção no corpo humano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |